Dr. Arterburn linked even short-term diabetes remission to less risk for microvascular kidney, eye, and limb diseases
Dr. David Arterburn reflects on CROSSROADS randomized controlled trial of Group Health patients with obesity and type 2 diabetes.
Dr. David Arterburn describes his research on Group Health patients’ weight after 2 years on various antidepressants
Research at Kaiser Permanente points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression.
UW and GHRI researchers have come up with innovative maps that illustrate the link between wealth accumulation and diet quality.
Dr. David Arterburn talks about his studies with Kaiser and other systems to help a rapidly increasing population with severe obesity.
Study leader Dr. David Arterburn will use PCORnet, new national clinical research network, to speed results.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.